Photoactivatable transition metal complexes are an attractive alternative to classic metal-based chemotherapeutic drugs. Light activation provides high spatial and temporal control of therapeutic action, potentially resulting in improved anticancer efficacy and lower side effects.1 Nevertheless, limited absorption features of transition metal complexes in the phototherapeutic window (600-1000 nm) hamper their advances towards preclinical and clinical stages. In this contribution, we present new promising strategies to integrate Ru and Pt prodrugs candidates with upconverting nanoparticles (UCNPs) and to use near infrared light (highly penetrating) for the in situ generation of biologically metal-based active species.2,3,4 Furthermore, the unique multimodal imaging capabilities of UCNPs (MRI/PET/UCL)5 make hybrid nanosystems of this kind encouraging candidates for theranostic applications. References [1] Ruggiero, E.; et al. Struct. Bond. 2014, 165, 69-108. [2] Ruggiero, E.; et al. Chem. Commun. 2014, 50, 1715-1718. [3] Ruggiero, E.; et al. Chem. Commun. 2015, 51, 2091-2095. [4] Ruggiero, E.; et al. Submitted. [5] Zhou, J.; et al. Chem. Soc. Rev. 2012, 41, 1323-1349. Acknowledgements Ramón y Cajal Fellowship RYC-2011-07787, Plan Nacional 2012CTQ2012-39315, MC CIG FP7 2012 PCIG11-GA-2012-321791, COST actions CM1105 and CM1403 for fruitful discussions.

Ruthenium and platinum antitumor complexes and their activation with 980-nm light

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.